Englund Tessa R, Kinlaw Alan C, Sheikh Saira Z
University of North Carolina at Chapel Hill.
ACR Open Rheumatol. 2020 Dec;2(12):760-766. doi: 10.1002/acr2.11207. Epub 2020 Dec 2.
The coronavirus disease 2019 (COVID-19) pandemic has led to rapid research and reporting on potential preventatives and treatments for the disease, including the drug hydroxychloroquine (HCQ). Despite a lack of robust evidence to support the use of HCQ for treatment of COVID-19, it was publicly endorsed and received widespread media coverage and public interest. The purpose of this report is to describe and contextualize the surges in public interest, demand, and adoption of HCQ for treatment of COVID-19 and outline implications for future public health policy and practice.
Using national and global events and Google Trends data as a measure of public interest, we describe the timeline and trends in the emergence of, interest in, and adoption of HCQ as a treatment of COVID-19. We additionally review reports on public demand for HCQ for treatment of COVID-19 and impacts on medication access among patients with indicated uses.
Public interest and demand for HCQ surged in the United States and globally following endorsements from public officials and enaction of policies to facilitate off-label use of HCQ for treatment of COVID-19. Surges in demand for HCQ led to multiple documented shortages and barriers to accessing HCQ treatment for patients with indicated uses for HCQ. Although there have been reversals in policies to support HCQ use for treatment of COVID-19 in some regions, others have continued or expanded recommended uses.
Insights from the global response to HCQ and COVID-19 can be used to inform prudent decision-making in the future to prevent premature action and promote informed and equitable responses to promote public health.
2019年冠状病毒病(COVID-19)大流行促使人们迅速开展对该疾病潜在预防措施和治疗方法的研究与报道,其中包括药物羟氯喹(HCQ)。尽管缺乏有力证据支持使用HCQ治疗COVID-19,但它得到了公开认可,并受到广泛的媒体报道和公众关注。本报告的目的是描述并将公众对HCQ治疗COVID-19的兴趣、需求和采用情况置于背景中进行分析,并概述其对未来公共卫生政策和实践的影响。
我们利用国家和全球事件以及谷歌趋势数据作为衡量公众兴趣的指标,描述了HCQ作为COVID-19治疗方法出现、受关注及被采用的时间线和趋势。我们还审查了关于公众对HCQ治疗COVID-19的需求以及对有适应症患者药物获取影响的报告。
在美国和全球范围内,随着政府官员的认可以及促进HCQ用于COVID-19治疗的非标签使用政策的实施,公众对HCQ的兴趣和需求激增。对HCQ需求的激增导致多次记录在案的短缺情况,以及有HCQ适应症的患者在获取HCQ治疗方面遇到障碍。尽管在一些地区支持使用HCQ治疗COVID-19的政策出现了逆转,但其他地区仍继续或扩大了推荐使用范围。
全球对HCQ和COVID-